SGLT2 Inhibitor for Cardiac Protection in a Patient With Osimertinib-Responsive Advanced EGFR-Positive Lung Cancer
Open Access
- 4 December 2024
- journal article
- case report
- Published by Elsevier in JACC: Case Reports
- Vol. 29 (23) , 102829
Abstract
No abstract availableKeywords
Funding Information
- NCI
This publication has 30 references indexed in Scilit:
- The Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Anthracycline-Treated Patients With CancerJACC: Cardiooncology, 2023
- Reoccurrence of takotsubo cardiomyopathy induced by osimertinib: A case reportClinical Case Reports, 2022
- The impact of SGLT2 inhibitors on inflammation: A systematic review and meta-analysis of studies in rodentsInternational Immunopharmacology, 2022
- Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With AnthracyclinesJACC: Heart Failure, 2022
- Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLCJournal of Thoracic Oncology, 2021
- Osimertinib-induced cardiac failure with QT prolongation and torsade de pointes in a patient with advanced pulmonary adenocarcinomaInternational Cancer Conference Journal, 2020
- Osimertinib-Induced CardiomyopathyJACC: Case Reports, 2020
- Heart Failure Associated With the Epidermal Growth Factor Receptor Inhibitor OsimertinibJACC: Cardiooncology, 2020
- Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With OsimertinibJACC: Cardiooncology, 2020
- Osimertinib-Induced CardiotoxicityJACC: Cardiooncology, 2019